Looking ahead to 2035, the cold packs market will experience consistent growth fueled by advancements in material science, ...

Shares of biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) have staged a notable rebound, with a single-day surge exceeding 5%, drawing market attention. This rally interrupts a nearly ...

Del Taco's quiet exit from Florida caps a costly experiment that erased hundreds of millions of dollars in value and ...

PEP's PBNA unit gains momentum through innovation and cost cuts, strengthening its path toward mid-teens margins by 2026.

Musk sees a future where AI reshapes work and productivity, predicting rapid deflation, talent scarcity and a world where ...

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of KYMBEEtm (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age ...

In this edition of ET Brand Equity’s cover, we examine how TVF has evolved from a YouTube start-up into a steady OTT ...

December 1, 2025Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAPBiodexa ...

Family-owned Anheuser-Busch wholesaler extends American Rebel Light’s patriotic footprint across northeast Arkansas with deep ...

Discover why Harrow Inc. (HROW) is a strong buy in 2024—explosive growth from Vevye, rising margins, and a $175 price target.

In the absence of AI profits, tech firms are retreating to what they know best – growth, growth and more growth.

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...